On August 6, Inogen (NASDAQ:INGN) reported second-quarter results that captured the company’s split personality right now. International sales keep compounding, new products are finding buyers, and profitability is improving. But the US business is still losing ground to a structural shift in how patients get oxygen therapy, and that weakness was enough to push full-year revenue guidance lower. The stock’s next stretch depends on whether the international and new-product engines can outrun the US drag before it does real damage.
Bull Case: Growth Where It Counts
International revenue hit $41.3 million in the quarter, up 15% year-over-year and the 10th straight quarter of double-digit growth there. Management pointed to expansion across Eastern Europe and Latin America and deeper distributor relationships as the driver, alongside recent launches of the Rove 6 portable oxygen concentrator in Canada and Brazil. Domestically, portable oxygen concentrator unit volume grew more than 12%, which the company says shows it is still taking share even as overall US revenue struggled.
The newer products are starting to matter too. Voxi, a stationary oxygen concentrator, has shipped more than 5,000 units and is aimed at a market Inogen pegs at $300 million in the US Aurora, its CPAP mask, more than doubled its customer count sequentially, and management estimates each point of share in the roughly $2.2 billion US CPAP mask market is worth about $20 million in revenue. Combined with airway clearance and digital health ambitions, Inogen says its addressable market has grown from about $400 million a year ago to more than $3.4 billion today.
Bear Case: Cracks In The Core
The US segment remains the problem. Total US sales fell 2% year over year to $42.3 million, and rental revenue dropped 12% to $11.6 million as more patients enter oxygen therapy directly through home medical equipment providers with a portable concentrator rather than through Inogen’s direct rental channel. That mix shift also weighed on the direct-to-consumer channel, even as the business-to-business channel grew mid-single digits.
Those pressures drove the guidance cut. Inogen now expects full-year 2026 revenue of $355 million to $361 million, down from a prior range of $366 million to $373 million, with third-quarter revenue expected to come in flat against the $92.4 million reported a year earlier. Management also flagged the timing of certain international distributor inventory purchases as a second-half headwind, adding uncertainty to a growth story that otherwise looks intact. The GAAP net loss was $3.9 million for the quarter, narrower than the $4.2 million loss a year earlier but a reminder the company is not yet consistently profitable.
Wall Street Keeps Its Distance
Hedge fund ownership of Inogen slipped from 23 funds to 20 quarter over quarter, a modest pullback rather than a rush for the exits. Short interest sits at 4.8% of the float, a level that suggests some organized skepticism but nothing close to a crowded short. Together, the two figures paint a market that is watching the US channel shift closely without betting heavily against the turnaround.
What Happens True
Inogen’s quarter shows a company generating real momentum abroad and in newer products while its legacy U.S. rental and direct-to-consumer business keeps shrinking under a structural shift toward home medical equipment providers. Adjusted EBITDA guidance actually rose to about $4 million for the year, so management is finding ways to protect profitability even as the top line comes in lighter than hoped.
While we acknowledge the risk and potential of INGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than INGN and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center